A French Real-life Study: EvaluatioN of durvALumab utilization and effectiveness for first line extensive stage small cell lung cancer.

Trial Identifier: D419QR00014
Sponsor: AstraZeneca
Collaborator:
Kappa Santé
NCTID:: NCT05683977
Start Date: November 2022
Primary Completion Date: April 2027
Study Completion Date: April 2027
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
France Nîmes, France, 30900
France Nîmes, France, 30900
France Nîmes, France, 30900
France Nîmes, France, 30900
France Nîmes, France, 30900
France Nîmes, France, 30900
France Nîmes, France, 30900
France Nîmes, France, 30900
France Nîmes, France, 30900
France Nîmes, France, 30900
France Nîmes, France, 30900
France Nîmes, France, 30900
France Nîmes, France, 30900
France Nîmes, France, 30900
France Nîmes, France, 30900
France Nîmes, France, 30900
France Nîmes, France, 30900
France Nîmes, France, 30900
France Nîmes, France, 30900
France Nîmes, France, 30900
France Nîmes, France, 30900
France Nîmes, France, 30900
France Nîmes, France, 30900
France Nîmes, France, 30900
France Nîmes, France, 30900
France Nîmes, France, 30900
France Nîmes, France, 30900
France Nîmes, France, 30900
France Nîmes, France, 30900
France Nîmes, France, 30900
France Nîmes, France, 30900
France Nîmes, France, 30900
France Nîmes, France, 30900
France RENNES, France